Latest Breaking News On - Giovanni landoni - Page 1 : comparemela.com

In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia. Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy MILAN, June 13, 2022 /PRNewswire/ Dompe farmaceutici S.p.A ("Dompe") today announcedresults from its Phase 2 clinical trial demonstrating that, in patients in severe COVID-19 Pneumonia, Reparixin led to an improvement in clinical outcomes when compared with the standard of care, a larger phase 3 clinical study is needed to confirm these results. Results from the Phase 2 trial are published in Infectious Diseases and Therapy and were presented at the scientific sessions of the ATS 2022 Internati

San francisco bayUnited statesSan franciscoFlavio mantelliGiovanni landoniDompe farmaceuticiInternational conferenceAmerican thoracic societyInfectious diseasesIntensive careHospital san raffaeleChief medical officerSan francisco bay areaIn hospitalized patients with covid 19 pneumoniaHe rates of clinical events among those treated with reparixinn 36 were statistically significantly lower than standard caren 19 the study is first evaluation efficacy and safety reparixin an il 8 inhibitor in patients severe covid pneumonia results from phase 2 trial presented at american thoracic society ats 2022 international conference published infectious diseases therapy milanJune 13